Neoadjuvant Chemotherapy for Ovarian Cancer: Chemo First, Surgery Second

Neoadjuvant chemotherapy is chemotherapy given before surgery, and for many women with advanced ovarian cancer, it has become one of the most common ways treatment begins.

That surprises people. Most of us assume ovarian cancer treatment follows a fixed order: surgery first, then drugs. Understanding why your team chose that order can change how the next several months feel.

Neoadjuvant Chemotherapy Definition: What the Word Actually Means

Here’s the neoadjuvant chemotherapy definition in plain language. In cancer care, adjuvant chemotherapy is chemo given after surgery. The “neo” flips the timing, so neoadjuvant chemotherapy is the same treatment given before surgery instead.

For advanced ovarian cancer, surgery and chemotherapy aren’t an either/or choice. Most patients need both. Neoadjuvant chemotherapy doesn’t change that. It changes the order.

The drugs are usually the same either way. What differs is the job. Chemo given first aims to shrink the disease so the surgeon can remove more of it. Chemo given after surgery goes after the cancer cells left behind.

Put them together and you get chemotherapy given ahead of the primary treatment, which for ovarian cancer is almost always surgery.

Its opposite is adjuvant chemotherapy, which comes after surgery. The drugs are usually the same, but the timing is different and so is the job.

You’ll also hear the shorthand NACT. And you’ll hear about the surgery that follows it, called interval debulking surgery or interval cytoreductive surgery. That’s the operation performed partway through your chemo course, once the tumor has shrunk.

The whole sequence looks roughly like this: a few cycles of chemo, then surgery, then a few more cycles of chemo.

Why Neoadjuvant Chemotherapy for Ovarian Cancer Exists at All

To understand why chemo-first became an option, you have to understand what ovarian cancer surgery is actually trying to accomplish.

The goal of debulking surgery for ovarian cancer is to remove every visible trace of disease. Decades of research keep landing on the same finding: how much cancer remains after surgery is one of the strongest predictors of how a patient does long-term.

But ovarian cancer is usually found late, after it has scattered across the abdomen. In those situations, achieving a complete removal in one operation may not be realistic. (Learn more: “Where Does Ovarian Cancer Spread?”)

Neoadjuvant chemotherapy changes the math. Shrink the disease first, and the operation that follows can be shorter, safer, and more likely to get everything.

Who Is a Candidate?

This decision belongs to a specialist. The American Society of Clinical Oncology’s guidelines are direct about it: anyone with suspected advanced ovarian cancer should be evaluated by a gynecologic oncologist before treatment starts, because assessing whether complete surgical removal is achievable takes specialized training and experience.

Generally, chemo-first is recommended in two situations.

The disease is too widespread to remove completely right now. If your surgeon assesses the spread and concludes that a first operation is unlikely to clear everything, chemotherapy first gives them a better shot.

Surgery would be too hard on your body. Age, other medical conditions, poor nutrition, fluid buildup in the abdomen, and general frailty all raise the risk of complications from a long operation. ASCO recommends neoadjuvant chemotherapy for patients whose risk profile makes major surgery dangerous.

There’s an equally important flip side. If you are well enough for surgery and your surgeon believes they can remove all visible disease, ASCO recommends going to the operating room first.

That doesn’t mean chemo-first is worse. Four large trials (EORTC 55971, CHORUS, JCOG0602, and SCORPION) found survival was similar with either approach. More recently, the TRUST trial, presented at ASCO in 2025, found that fit patients who had surgery first at expert centers went longer before their cancer progressed. Their overall survival was also longer, though not by a statistically significant margin.

Neither path is wrong. It’s about which one fits you.

What Happens Before Your First Infusion

This part gets skipped in a lot of explanations, and it matters more than people realize.

Before neoadjuvant chemotherapy begins, your team needs to confirm what they’re treating. Scans alone can’t do that. Other cancers, including uterine and gastrointestinal cancers, can look similar on imaging, and a mass isn’t always malignant. 

So ASCO recommends a tissue biopsy before chemo starts, and specifically a core biopsy rather than a fine-needle aspiration (FNA).

The difference is in what each one collects. An FNA uses a very thin needle to draw out loose cells. A core biopsy uses a slightly larger hollow needle, usually guided by ultrasound or CT, to remove a small cylinder of intact tissue.

Loose cells can show that something is abnormal, but they can’t always show how it’s behaving. Telling a borderline ovarian tumor apart from invasive ovarian cancer depends on seeing whether abnormal cells are growing into the surrounding tissue, and that takes intact tissue. A core sample also usually provides enough material for tumor genetic testing, which can shape your treatment options later.

Timing matters, too. Once chemotherapy has done its work, the tissue removed at surgery may be too damaged for accurate analysis. Getting enough tissue upfront protects that.

This is also when genetic testing should happen. ASCO recommends that everyone diagnosed with ovarian cancer be offered both inherited and tumor genetic testing at diagnosis. Results can open doors to maintenance treatments like PARP inhibitors and tell your relatives something meaningful about their own risk. 

If nobody has mentioned genetic testing to you, ask. It’s a reasonable question and a standard recommendation.

How Is Neoadjuvant Chemotherapy Administered?

For anyone wondering how neoadjuvant chemotherapy is administered, the practical answer is that it looks and feels like standard chemotherapy for ovarian cancer.

Drugs go in through a vein, typically through a port placed under the skin of your chest so you’re not getting stuck repeatedly. Treatment runs in cycles, usually one infusion every three weeks, with recovery time built in between.

The standard combination pairs a platinum drug with a taxane. Carboplatin and paclitaxel are the most common pairing. ASCO recommends this two-drug combination rather than a single drug, because trials have shown single-agent treatment performs worse, even in older and more fragile patients.

Between cycles, your team monitors closely. That usually means physical exams, CA-125 blood tests, and a scan after about three cycles compared against your baseline imaging.

When Does the Surgery Happen?

ASCO recommends that interval surgery happen after no more than four cycles of chemotherapy, as long as three things are true: the cancer is responding, the surgeon believes complete removal is now achievable, and you’re physically well enough for a major operation.

That last point matters. Chemotherapy takes a toll, and some patients aren’t strong enough for interval surgery when the time comes. If the risks of the operation outweigh the benefits, your team may recommend continuing chemotherapy instead.

Most patients receive three or four cycles first, then have surgery, then complete a total of at least six cycles overall.

For some patients, one additional option comes up during that operation: heated chemotherapy delivered directly into the abdomen at the time of surgery. We explain that procedure in our guide to HIPEC. 

This may be offered to patients with stage III disease who are in reasonably good health with adequate kidney function, and notes it requires a center specifically equipped to deliver it.

Does Neoadjuvant Chemotherapy Improve Survival?

Does neoadjuvant chemotherapy improve survival compared to surgery first? Based on the major randomized trials, the answer is that it doesn’t appear to improve survival, and it doesn’t appear to worsen it either.

Four large trials, known as EORTC 55971, CHORUS, JCOG0602, and SCORPION, compared the two approaches. A 2026 review then pooled those four with the newer TRUST trial, covering 2,380 women in all. It found almost identical overall survival whether women had chemotherapy or surgery first, and rated that finding as high-certainty evidence. Progression-free survival was likely similar, too.

That’s a large body of evidence pointing to the same conclusion, which is why both approaches are considered legitimate standards of care.

Where the difference shows up clearly is in what patients go through.

In the CHORUS trial, serious complications after surgery occurred in 14% of women who had chemotherapy first, compared to 24% of those who went to surgery first. Deaths within 28 days of the operation were also lower with chemo first. That gap is the strongest argument for this approach.

The shrinkage is real, too. In EORTC 55971, surgeons removed all visible disease in 51% of women treated with chemotherapy first, compared to 19% of those who had surgery first. 

Complete removal is one of the strongest predictors of long-term outcomes, so more than doubling those odds matters. Quality-of-life measures across the trials either favored chemo first or showed no meaningful difference.

There’s one group where the picture leans further. In a combined long-term analysis of the EORTC and CHORUS trials, women with stage IV disease, meaning cancer that had spread beyond the abdomen, lived longer with chemotherapy first. For that group, the sequence appears to genuinely matter.

It’s also worth knowing these trials have real critics. In EORTC 55971 and CHORUS, surgeons achieved complete removal in only 19% and 16% of the surgery-first patients, with median operating times of under three hours. 

Some surgeons have argued that’s well below what an experienced team at a high-volume center accomplishes, where complete removal rates commonly reach 50% to 70%. If the surgery arm was underperforming, the comparison may have been tilted from the start. 

That’s exactly what the TRUST trial set out to test. With surgery done at accredited expert centers, operating first extended the time before the cancer progressed, though the overall survival advantage didn’t reach statistical significance.

So the takeaway isn’t that one approach beats the other. Both are legitimate, and matching the right one to the right patient is what actually matters. 

Why This Looks Different for Rare Subtypes

Here’s something that gets lost in general chemotherapy explanations, and it’s central to why Not These Ovaries exists.

Nearly all of the research behind neoadjuvant chemotherapy was done in high-grade serous ovarian cancer. That subtype responds well to platinum chemotherapy. The trials were built around it.

Low-grade serous ovarian cancer behaves differently. It grows slowly, and chemotherapy works best against fast-dividing cells, which means standard chemo often doesn’t produce the shrinkage you’d hope for. Our article on chemotherapy for LGSOC goes deeper into why response rates stay stubbornly low.

ASCO acknowledges this directly. The guideline notes that surgery first may be preferred for subtypes where chemotherapy response is especially low, including low-grade serous and clear cell ovarian cancer. For mucinous tumors, different drug combinations may be considered.

The panel also strongly encourages clinical trial participation for these patients, because the standard playbook was written for a different disease.

What If the Cancer Doesn’t Respond?

Sometimes the tumor grows during chemotherapy. It’s uncommon, but it happens.

If the disease progresses on treatment, ASCO recommends a repeat biopsy to confirm the diagnosis and re-examine the tumor’s biology. Surgery generally isn’t recommended in this situation, unless it’s needed to relieve a specific problem such as a blocked bowel, because a complete removal is unlikely and the operation carries real risk.

Instead, the conversation shifts. Cancer that grows during first-line chemotherapy is called platinum-refractory, and the prognosis is difficult. According to ASCO’s guideline, median survival in this situation is less than one year.

That makes this the time for an honest goals-of-care conversation with your team about what matters most to you and how you want to spend the time ahead. Options include different chemotherapy drugs, clinical trials, or stopping active cancer treatment and moving to end-of-life care. The guideline names all three. Choosing to stop treatment is a recognized option.  

Whatever you decide, palliative care can help. ASCO recommends considering it early for anyone with a heavy symptom burden. It focuses on comfort and quality of life, and it can run alongside treatment or continue after treatment stops.

Questions Worth Asking

If neoadjuvant chemotherapy is on the table, these are reasonable things to bring to your appointment:

• Why are you recommending chemotherapy before surgery in my case?
• Has a gynecologic oncologist evaluated whether surgery first is possible?
• Has my diagnosis been confirmed with a tissue biopsy?
• Have I been offered genetic and tumor testing?
• How many cycles do you expect before surgery, and how will you decide when it’s time?
• What subtype do I have, and does that affect how well chemo is likely to work?
• Are there clinical trials I should know about?

You’re allowed to ask all of them. Write them down. Bring someone with you who can take notes while you listen.

Ask Until You Understand Why

Neoadjuvant chemotherapy shifts the order of ovarian cancer treatment for a specific reason: to make a difficult surgery more successful and less dangerous. The evidence suggests it doesn’t extend survival compared to operating first, but it consistently reduces surgical complications, and for some patients it’s the only way a complete removal becomes possible.

What matters most is that the choice is made deliberately, by a specialist, for reasons that fit your situation.